Abstract
Stroke is a common disease, which is associated with high morbidity and high mortality. Up to 25% of cerebral ischaemic infarcts are caused by cardio-embolic events, most commonly associated with atrial fibrillation. It has previously been shown that antithrombotic therapy is insufficiently used in patients at increased risk of stroke. This article reviews evidence and practical management of anticoagulant therapy in stroke patients and provides an update on risk stratification for thromboembolism and bleeding complications in patients with atrial fibrillation.
MeSH terms
-
Aged
-
Anticoagulants / adverse effects*
-
Anticoagulants / therapeutic use
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy
-
Benzimidazoles / administration & dosage
-
Benzimidazoles / adverse effects
-
Benzimidazoles / therapeutic use
-
Brain Ischemia / diagnostic imaging
-
Cerebral Hemorrhage / chemically induced
-
Dabigatran
-
Female
-
Humans
-
Male
-
Morpholines / administration & dosage
-
Morpholines / adverse effects
-
Morpholines / therapeutic use
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Pyridones / administration & dosage
-
Pyridones / adverse effects
-
Pyridones / therapeutic use
-
Radiography
-
Risk Assessment
-
Risk Factors
-
Secondary Prevention
-
Stroke / prevention & control*
-
Thiophenes / administration & dosage
-
Thiophenes / adverse effects
-
Thiophenes / therapeutic use
-
Thromboembolism / chemically induced
-
Vitamin K / antagonists & inhibitors*
-
beta-Alanine / administration & dosage
-
beta-Alanine / adverse effects
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / therapeutic use
Substances
-
Anticoagulants
-
Benzimidazoles
-
Morpholines
-
Pyrazoles
-
Pyridones
-
Thiophenes
-
beta-Alanine
-
Vitamin K
-
Dabigatran